Institut De Cancerologie De Lorraine

The medical center is at the forefront of research in head and neck carcinoma, focusing on innovative therapies that aim to preserve lymphocytes while enhancing the efficacy of radio-immunotherapy. This approach is particularly beneficial for patients with lateralised oropharyngeal, laryngeal, and hypopharyngeal squamous cell carcinoma.

• Lymphocyte-Sparing Techniques
• Radio-Immunotherapy Innovations
• Squamous Cell Carcinoma Management

By integrating advanced radiotherapy techniques with novel agents like all-trans retinoic acid, the center is pioneering treatments that aim to improve patient outcomes while minimizing adverse effects.

Specializing in HER2-positive breast cancer, the center is exploring therapeutic de-escalation strategies for patients with controlled disease. This research is crucial for reducing treatment burden while maintaining efficacy in metastatic cases.

• Therapeutic De-escalation
• Circulating Tumor DNA Analysis
• HER2-Targeted Therapies

The center's work in this area is paving the way for more personalized treatment plans that align with the molecular profile of the cancer, potentially leading to better quality of life for patients.

Research at the center is advancing the treatment of renal cell carcinoma through the study of combination therapies involving tivozanib and nivolumab. These efforts are aimed at improving progression-free survival in patients who have previously undergone immune checkpoint inhibitor therapy.

• Combination Therapy Efficacy
• Immune Checkpoint Inhibitors
• Progression-Free Survival

By focusing on innovative drug combinations, the center is contributing to the development of more effective treatment regimens for renal cell carcinoma.

The center is conducting pivotal research in epithelial ovarian cancer, primary peritoneal, and fallopian tube cancers, particularly in cases resistant to platinum-based therapies. This research is crucial for developing new treatment options for high-grade cancers with high folate receptor-alpha expression.

• Platinum-Resistant Cancer Strategies
• Folate Receptor-Alpha Targeting
• Advanced Therapeutic Options

Through comparative studies of novel agents against standard chemotherapy, the center is striving to enhance survival rates and quality of life for affected patients.

Focusing on carcinosarcoma, the center is evaluating the efficacy of combining dostarlimab with niraparib versus monotherapy. This research is essential for improving treatment outcomes in metastatic or recurrent cases.

• Combination Therapy Evaluation
• Metastatic Carcinosarcoma Management
• Innovative Drug Trials

By identifying the most effective treatment strategies, the center is enhancing therapeutic options for patients with these aggressive cancers.

The center is advancing the treatment of prostate cancer through studies on darolutamide in combination with androgen deprivation therapy. This research is pivotal for improving radiographic progression-free survival in biochemically recurrent cases.

• Androgen Deprivation Strategies
• Radiographic Progression-Free Survival
• Advanced Imaging Techniques

By integrating advanced imaging and therapeutic techniques, the center is setting new standards in the management of prostate cancer.